Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Inb-100: Pilot Study of Donor Derived, Ex-Vivo Expanded/Activated Gamma Delta T Cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-Transplant Cyclophosphamide

Joseph P. McGuirk, Sunil Abhyankar, Trishna Goswami, Mariska ter Haak, Kate Rochlin, Lawrence S. Lamb

Blood (2024) 144 (Supplement 1): 4823.

https://doi.org/10.1182/blood-2024-199153

Published: 2024

Journal Articles

Inb-100: A Pilot Study of Donor Derived, Ex-Vivo Expanded/Activated Gamma-Delta T Cell (EAGD) Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-Transplant Cyclophosphamide (PTCy)

Joseph P McGuirk, Sunil Abhyankar, Trishna Goswami, Halie Juarez, Mariska ter Haak, Tyce Bruns, Samantha Youngblood, Lawrence S. Lamb

Blood (2023) 142 (Supplement 1): 4853.

https://doi.org/10.1182/blood-2023-181184

Published: 2023

Journal Articles

Relapse Prophylaxis Post-Haploidentical Bone Marrow Transplantation and Cyclophosphamide (Haplo/Cy) By Infusion of Donor-Derived Expanded/Activated Gd T Cells: A Phase I Trial

Joseph P. McGuirk, Sunil H Abhyankar, Trishna Goswami, Rupal Soder, Mariska ter Haak, Tyce Bruns, Samantha Langford Youngblood, Lawrence S. Lamb, Jr.

Blood (2022) 140 (Supplement 1): 7464–7465.

https://doi.org/10.1182/blood-2022-169819

Published: 2022

Journal Articles

Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2017) 130 (Supplement 1): 1298.

https://doi.org/10.1182/blood.V130.Suppl_1.1298.1298

Published: 2017

Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD)

Blood (2017) 130 (Supplement 1): 2583.

https://doi.org/10.1182/blood.V130.Suppl_1.2583.2583

Published: 2017

Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis

Mrinal M. Patnaik, MDMBBS, Vikas Gupta, MD PhD, Gary J. Schiller, Sangmin Lee, MD, Abdulraheem Yacoub, MD, Haris Ali, MD, Moshe Talpaz, MD, Megan Sardone, Halyna Wysowskyj, Shay Shemesh, Janice Chen, PhD, Christopher Brooks, PhD, Trishna Goswami, MD, Animesh Pardanani, MBBS PhD, Ayalew Tefferi, MD, Srdan Verstovsek, MD PhD, Joseph David Khoury, MD, Naveen Pemmaraju, MD

Blood (2017) 130 (Supplement 1): 2908.

https://doi.org/10.1182/blood.V130.Suppl_1.2908.2908

Published: 2017

Journal Articles

Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia

Douglas Gladstone, MD, Marc Andre, MD PhD, Jan Zaucha, MD PhD, Sarit Assouline, MD MSc, Naresh Bellam, MD MPH, Nicole Cascavilla, MD, Eric Jourdan, MD PhD, Amit Panwalkar, MD, Caterina Patti, MD, Clemens Schulte, MD, Francesco Zaja, MD, Trishna Goswami, MD, Nairouz Elgeioushi, MPH, Katie Streicher, PhD, Haifeng Bao, PhD, David Spaner, MD FRCPC, PhD

Blood (2014) 124 (21): 4472.

https://doi.org/10.1182/blood.V124.21.4472.4472

Published: 2014

Journal Articles

A microRNA Signature Predicts Response to Anti-CD19 Therapy (MEDI-551) in B-Cell Malignancies

Katie Streicher, PhD, Philip Brohawn, Mike Kuziora, Fernanda Pilataxi, Brandon Higgs, Kim Lehmann, Kathleen McKeever, Trishna Goswami, MD, Ronald Herbst, PhD, Yihong Yao, Koustubh Ranade

Blood (2014) 124 (21): 2198.

https://doi.org/10.1182/blood.V124.21.2198.2198

Published: 2014

Journal Articles

Design Of a Phase 1/2 Study Of Moxetumomab Pasudotox In Adult Patients With Relapsed and/Or Refractory Acute Lymphoblastic Leukemia (ALL)

Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Trishna Goswami, MD, Fujun Wang, PhD, Ramy Ibrahim, MD

Blood (2013) 122 (21): 5021.

https://doi.org/10.1182/blood.V122.21.5021.5021

Published: 2013

Journal Articles

Interrogation Of Signaling Networks In B Cell Malignancies To Improve Classification Of Patient Subsets For Targeted Therapy

Joyce Obidi, Patricia Burke, Trishna Goswami, Laura Richman, Dirk Mendel, Haifeng Bao

Blood (2013) 122 (21): 1786.

https://doi.org/10.1182/blood.V122.21.1786.1786

Published: 2013

Journal Articles

Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies

Andres Forero-Torres, MD, Mehdi Hamadani, MD, Michelle A. Fanale, MD, Celeste M. Bello, MD, Thomas J. Kipps, MD, PhD, Fritz Offner, MD, Gregor Verhoef, Massimo Federico, MD, Stephanie A. Gregory, MD, Anne Sonet, MD, Sarit Assouline, MD, Jaime Pérez de Oteyza, Jose Francisco Tomas, MD, Antonio Cuneo, MD, Nairouz Elgeioushi, MPH, Trishna Goswami, MD, Ramy Ibrahim, MD, Ronald Herbst, PhD, Bruce D. Cheson, M.D.

Blood (2013) 122 (21): 1810.

https://doi.org/10.1182/blood.V122.21.1810.1810

Published: 2013

Journal Articles

MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study

Blood (2012) 120 (21): 3677.

https://doi.org/10.1182/blood.V120.21.3677.3677

Published: 2012

Journal Articles

Bendamustine and Lenalidomide in Relapsed/Refractory CLL

Chaitra S. Ujjani, MD, Syed M. Karim, MD, Trishna Goswami, MD, Jenny Crawford, Edmund A Gehan, Craig M. Kessler, MD, Bruce D. Cheson, MD

Blood (2011) 118 (21): 4618.

https://doi.org/10.1182/blood.V118.21.4618.4618

Published: 2011

NARROW

Inb-100: Pilot Study of Donor Derived, Ex-Vivo Expanded/Activated Gamma Delta T Cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-Transplant Cyclophosphamide

Inb-100: A Pilot Study of Donor Derived, Ex-Vivo Expanded/Activated Gamma-Delta T Cell (EAGD) Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-Transplant Cyclophosphamide (PTCy)

Relapse Prophylaxis Post-Haploidentical Bone Marrow Transplantation and Cyclophosphamide (Haplo/Cy) By Infusion of Donor-Derived Expanded/Activated Gd T Cells: A Phase I Trial

Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Results from Ongoing Phase 1/2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD)

Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis

Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia

A microRNA Signature Predicts Response to Anti-CD19 Therapy (MEDI-551) in B-Cell Malignancies

Design Of a Phase 1/2 Study Of Moxetumomab Pasudotox In Adult Patients With Relapsed and/Or Refractory Acute Lymphoblastic Leukemia (ALL)

Interrogation Of Signaling Networks In B Cell Malignancies To Improve Classification Of Patient Subsets For Targeted Therapy

Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies

MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study

Bendamustine and Lenalidomide in Relapsed/Refractory CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only